SCHEMBL2838367

SCHEMBL2838367

CC(C)(C)OC(=O)NC(C(=O)c1ccc(OC2CCSCC2)cc1)c1ccc(Cl)c(Cl)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR3 Q99500 3/20 0.43
MDM2 Q00987 1/20 0.37
S1PR2 O95136 1/20 0.36
S1PR4 O95977 1/20 0.36
ALDH1A1 P00352 1/20 0.36
EPHX2 P34913 3/20 0.35
RAF1 P04049 2/20 0.35
SLC6A3 Q01959 3/20 0.35
ACACB O00763 3/20 0.35
UTS2R Q9UKP6 1/20 0.33
CTSS P25774 1/20 0.33
CTSK P43235 1/20 0.33
CCR2 P41597 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
SLC6A2 P23975 1/20 0.33
SLC6A4 P31645 1/20 0.33
HRH1 P35367 1/20 0.33
CCR3 P51677 1/20 0.33
KCNH2 Q12809 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2838790 0.88 S1PR3 (0.42) S1PR3MDM2S1PR2S1PR4EPHX2
SCHEMBL2833228 0.86 S1PR3 (0.43) S1PR3EPHX2ACACBMEN1KMT2A
SCHEMBL2832356 0.85 S1PR3 (0.42) S1PR3MDM2ACACB
SCHEMBL2835645 0.82 ACACB (0.41) S1PR3ACACB
SCHEMBL2838253 0.81 S1PR3 (0.46) S1PR3MDM2ACACBHRH1
SCHEMBL2839888 0.81 CACNA1B (0.46) S1PR3ALDH1A1EPHX2ACACBCTSS
SCHEMBL2835001 0.80 S1PR3 (0.48) S1PR3MDM2S1PR4ALDH1A1CTSS
SCHEMBL2833789 0.80 CACNA1B (0.46) S1PR3ALDH1A1EPHX2ACACBCTSS
SCHEMBL2832303 0.79 S1PR3 (0.49) S1PR3MDM2S1PR4UTS2RCTSS
SCHEMBL2836642 0.79 S1PR3 (0.48) S1PR3MDM2S1PR4ALDH1A1CTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8367838-B2 Amines or amino alcohols as GLYT1 inhibitors HOFFMANN-LA ROCHE INC. (US) 2013-02-05 US disclosed
US-20120232033-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS KOLCZEWSKI SABINE (DE) 2012-09-13 US disclosed
EP-2398558-A1 AMINE OR AMINO ALCOHOLS AS GLYT1 INHIBITORS F. Hoffmann-La Roche AG (CH) 2011-12-28 EP disclosed
WO-2010094659-A1 AMINE OR AMINO ALCOHOLS AS GLYT1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2010-08-26 WO disclosed
US-20100210592-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS HOFFMANN-LA ROCHE, INC. 2010-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120232033-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS GFPT1, CEPT1, SLC18A2 S1PR3 2311/4885MDM2 4155/4885S1PR2 2460/4885
US-20100210592-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS GFPT1, CEPT1, SLC18A2 S1PR3 2311/4885MDM2 4155/4885S1PR2 2460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.